MorphoSys as a partner

With its longstanding expertise in antibody engineering, proven development capabilities and leading technologies, MorphoSys is a qualified partner in the industry for drug discovery and the development of biologics.

MorphoSys’s worldwide partnering track record spans a wide range of agreements, from collaborations with academia and innovative biopharmaceutical start-ups to drug discovery alliances with several of the largest pharmaceutical companies like Novartis, Roche, Johnson & Johnson/Janssen, Pfizer, Bayer and Boehringer Ingelheim. For the further development and commercialization of our proprietary clinical-stage programs we have been able to attract GlaxoSmithKline, amongst others. These productive partnerships have resulted in one of the largest therapeutic antibody pipelines to date.

MorphoSys is dedicated to becoming a fully integrated biopharmaceutical company including late-stage clinical development and marketing/co-promotion of its own drugs. With our goal of engineering the medicines of tomorrow in mind, we are always interested in new collaborations with innovative, science-driven organizations and academic institutions.

MorphoSys has a proven track record of successful alliances including research and development agreements with a number of leading pharmaceutical and biotechnology companies.

Innovation Capital

Lara Smith-Weber

SENIOR VICE PRESIDENT, Head of Controlling, Corporate Finance & Corporate Development

Phone: +49 (0)89 89927 478

Email Contact

Please note: MorphoSys has a specific procedure for receiving and processing confidential or proprietary information from external sources. Please contact us to obtain the details of this procedure before sending any such information. For that reason, all unsolicited submissions of any kind will be treated as non-confidential and non-proprietary and MorphoSys may freely use any ideas, inventions or anything else contained in your submission.